ASCO 2020：11项华北地区研究入选口头报告，17项Poster报告

受当今世界新冠霍乱影响，原定于5月29日~6月2日在芝加哥举行的英国外科学不会（ASCO）年不会今年将首次以线上多种形式举办，这是目前最大规模的线上盛不会。以前，全体不会议的简短考题定为，共103个sessions，里国共有11项深入研究入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡洛替尼加卡培他滨用做HER2+白血病乳癌症（PHOEBE）：一项III期随机试验性。

第二场：白血病乳癌症

写作者：里国医学科学院诊所徐兵河讲师、马飞讲师，清华大学附属诊所胡夕春讲师等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性乳癌症标准治疗法后卡培他滨延续节拍化疗的III期试验性（SYSUCC-001）。

第二场：乳癌症—大面积/区域/辅助治疗法

写作者：永康大学防控为里心王树森讲师等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用白血病脑的性状相似性来预测脑脊液里循环DNA检测的随机性: 新工具对抗据传对手

第二场：新工具解决据传难题

写作者：陈美芹 陈德兰等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为里晚期大肠细胞内癌症的三线治疗法：一项开放标识、随机、多为里心II/III期试验性。

第二场：消化道癌症—十二指肠冠状动脉、坏死和大肠胆

写作者：重庆大学华西诊所毕锋讲师、里国人民解放军八一诊所秦叔逵讲师等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国里晚期大肠癌症病患阿帕替尼双线治疗法：一项随机、安慰剂比对、双盲III期深入研究

第二场：消化道癌症—十二指肠冠状动脉、坏死和大肠胆

写作者：里国人民解放军八一诊所秦叔逵讲师、重庆大学华西诊所陈秋讲师等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

里晚期中风性卵巢癌症二次细胞内减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

研讨：妇产科结核病

写作者：清华大学附属永康诊所臧荣余讲师等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈癌症根治性子宫切除术后辅助治疗法里的序贯放化疗对比之外放射治疗或同步放化疗（STARS深入研究）：一项随机、比对、开放标识的III期试验性。

全体不会议：妇产科结核病

写作者：永康大学防控为里心黄鹤讲师、刘继红讲师等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比化疗用做可切除的EGFR等位基因的N1-N2期NSCLC-随机III期外科试验性的最终总体穴居深入研究。

研讨：肺癌症—非小细胞内大面积-区域/小细胞内/其他胸部

写作者：珠海市人民诊所吴一龙讲师等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因寡转移非小细胞内肺癌症病患三线酪氨酸激酶抑制剂联合行动或不联合行动鼓励前线大面积放射治疗：III期开放标识外科随机试验性（SINDAS）的里期结果（NCT02893332）。

研讨：肺癌症-非小细胞内转移

写作者：四川省人民诊所曾铭讲师等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性生还-1（PD-1）的人源化IgG4单克隆抗体联合行动阿昔替尼用做白血病粘膜前列腺癌症病患的Ib期深入研究的总穴居期和生物标志物深入研究。

研讨：前列腺癌症/皮肤癌症

写作者：华东师范大学诊所郭军、盛锡楠讲师等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可靠性和结果：通用CAR-T细胞内首次人体试验性治疗法中风/难治性T细胞内急性红细胞内白血病（r/r T-ALL）的可靠性和。全体不会议：开发设计里的治疗法技术-免疫治疗法。写作者：朱明欣等简短：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在里晚期冠状动脉上皮细胞细胞内癌症病患里的应用：一项随机的开放标识II期试验性（ORIENT-2）。全体不会议：消化道癌症-十二指肠冠状动脉癌症、心肌梗塞症和大肠胆道癌症写作者：徐建明讲师等简短：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T细胞内对质母细胞内瘤的遏止性治疗法全体不会议：里枢神经系统写作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东简短：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在里晚期错配修复缺陷病患里的应用全体不会议：开发设计里的治疗法学-免疫治疗法写作者：沈琳讲师等简短：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 暂时性CD7-CART治疗法中风/难治性ACUTE红细胞内白血病/淋巴瘤的首例人体外科试验性全体不会议: 开发设计性治疗法学-免疫治疗法写作者简介：张明志，杨林等简短：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 昂替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合行动应用做里晚期实体瘤病患的Ib期深入研究全体不会议：发展性治疗法学--小分子基因表达药物和生物学写作者：龚继芳，沈琳讲师等简短：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动制剂和nedaplatin治疗法中风性或白血病冠状动脉上皮细胞细胞内癌症（ESCC）病患的II期深入研究。全体不会议：消化道癌症-十二指肠冠状动脉、坏死和大肠胆道癌症的深入研究写作者：王志强，陈玉红，王德申，王凤华，任超，谭琼 王志强、陈玉红、王德深、王凤华、任超、谭琼简短：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体不会议：消化道癌症-十二指肠冠状动脉癌症、心肌梗塞症和大肠胆管癌症的双线治疗法写作者：宋艳等简短：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环RNA方差用做初始活检时检测高等级癌症的尿液外体环RNA方差：一项多为里心的回顾性深入研究全体不会议：泌尿上皮细胞结核病那是癌症、睾丸癌症和癌症写作者简介：Liaoyuan Li等简短：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积里晚期宫颈癌症并发化疗后的辅助化疗全体不会议: 妇产科结核病写作者简介： 陈珉珉等简短：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法甲状腺质性癌症的相关性：基于ALTER01031试验性的深入研究。不会话：皮脂腺写作者：天津诊所高明讲师简短：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼治疗法后病患剧情的影响: ALTER01031的亚组深入研究全体不会议：皮脂腺写作者：天津诊所高明讲师简短：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究预测I-IIIA期非小细胞内肺癌症（NSCLC）病患术后中风: GASTO1035和GASTO1018的结果全体不会议：肺癌症-非小细胞内大面积-区域性/小细胞内/小细胞内/其他胸科结核病写作者：Si-Yu Wang等简短：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞内肺癌症（NSCLC）里EGFR酪氨酸激酶抑制剂的新型耐药机制全体不会议:肺癌症-非小细胞内白血病肺癌症写作者简介：赵昕，金玲玲，满宇，欧西厢记，湛，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧西厢记、湛、薛武、杨绍、范敏简短：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性里里晚期前列腺癌症总穴居的替代终点全体不会议：前列腺癌症/皮肤癌症写作者：聂润聪，袁书强，陈元芳，陈英波，周志伟 聂润聪、袁书强、陈元芳、陈英波、周志伟简短：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法中风或白血病原发性恶性骨病患的II期深入研究全体不会议： 遗传性写作者：唐丽娜，牛晓辉，王稼祥，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简短：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评分安罗替尼在里晚期遗传性病患多线治疗法里的可靠性和。全体不会议：遗传性写作者：姚伟涛，王家强，张鹏，朱明，杜新辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英简短：11526宣传品：414